Kyverna Therapeutics (KYTX)

• Market cap: $525M
• 1 day: -3.19%
• 5 days: -4.56%
• 1 month: 15.94%
• 3 months: 27.35%
• 6 months: 101.37%
• Year to date: 0.34%
• 1 year: 246.46%
• 5 years: -70.67%
• 10 years: -70.67%
• Sector: Healthcare
• Industry: Biotechnology

About: Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Employees: 129